

Claudia Manzoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/175696/publications.pdf>

Version: 2024-02-01

59
papers

9,561
citations

185998

28
h-index

143772

57
g-index

65
all docs

65
docs citations

65
times ranked

20925
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
2	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology</i> , The, 2019, 18, 1091-1102.	4.9	1,414
3	Genome, transcriptome and proteome: the rise of omics data and their integration in biomedical sciences. <i>Briefings in Bioinformatics</i> , 2018, 19, 286-302.	3.2	498
4	Synthetic amyloid- β oligomers impair long-term memory independently of cellular prion protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 2295-2300.	3.3	435
5	A Recessive Mutation in the APP Gene with Dominant-Negative Effect on Amyloidogenesis. <i>Science</i> , 2009, 323, 1473-1477.	6.0	357
6	The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by α -synuclein or amyloid- β (1-42) peptide. <i>Journal of Neurochemistry</i> , 2009, 110, 1445-1456.	2.1	241
7	Genetic and phenotypic characterization of complex hereditary spastic paraplegia. <i>Brain</i> , 2016, 139, 1904-1918.	3.7	170
8	Cellular processes associated with $LRRK2$ function and dysfunction. <i>FEBS Journal</i> , 2015, 282, 2806-2826.	2.2	144
9	Inhibition of LRRK2 kinase activity stimulates macroautophagy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2013, 1833, 2900-2910.	1.9	124
10	Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. <i>JAMA Neurology</i> , 2021, 78, 464.	4.5	95
11	Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation. <i>Biochemical and Biophysical Research Communications</i> , 2013, 441, 862-866.	1.0	79
12	mTOR independent regulation of macroautophagy by Leucine Rich Repeat Kinase 2 via Beclin-1. <i>Scientific Reports</i> , 2016, 6, 35106.	1.6	69
13	LRRK2 and Human Disease: A Complicated Question or a Question of Complexes?. <i>Science Signaling</i> , 2012, 5, pe2.	1.6	64
14	Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies. <i>FASEB Journal</i> , 2013, 27, 3424-3429.	0.2	61
15	The LRRK2-macroautophagy axis and its relevance to Parkinson's disease. <i>Biochemical Society Transactions</i> , 2017, 45, 155-162.	1.6	58
16	Genetics and molecular mechanisms of frontotemporal lobar degeneration: an update and future avenues. <i>Neurobiology of Aging</i> , 2019, 78, 98-110.	1.5	57
17	Conformational Plasticity of the Gerstmann-Strussler-Scheinker Disease Peptide as Indicated by Its Multiple Aggregation Pathways. <i>Journal of Molecular Biology</i> , 2008, 381, 1349-1361.	2.0	56
18	LRRK2 and Autophagy. <i>Advances in Neurobiology</i> , 2017, 14, 89-105.	1.3	54

#	ARTICLE	IF	CITATIONS
19	Tetracycline prevents A β oligomer toxicity through an atypical supramolecular interaction. <i>Organic and Biomolecular Chemistry</i> , 2011, 9, 463-472.	1.5	52
20	Computational analysis of the LRRK2 interactome. <i>PeerJ</i> , 2015, 3, e778.	0.9	48
21	Divergent α -synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases. <i>Neurobiology of Disease</i> , 2013, 58, 183-190.	2.1	44
22	The Molecular Assembly of Amyloid A β Controls Its Neurotoxicity and Binding to Cellular Proteins. <i>PLoS ONE</i> , 2011, 6, e24909.	1.1	39
23	Weighted Protein Interaction Network Analysis of Frontotemporal Dementia. <i>Journal of Proteome Research</i> , 2017, 16, 999-1013.	1.8	39
24	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. <i>Brain</i> , 2018, 141, 2895-2907.	3.7	39
25	Overcoming synthetic A β peptide aging: a new approach to an age-old problem. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2009, 16, 71-80.	1.4	36
26	Neurotoxic and Gliotrophic Activity of a Synthetic Peptide Homologous to Gerstmann-Straussler-Scheinker Disease Amyloid Protein. <i>Journal of Neuroscience</i> , 2007, 27, 1576-1583.	1.7	35
27	Stratification of candidate genes for Parkinson's disease using weighted protein-protein interaction network analysis. <i>BMC Genomics</i> , 2018, 19, 452.	1.2	35
28	Comparative Protein Interaction Network Analysis Identifies Shared and Distinct Functions for the Human ROCO Proteins. <i>Proteomics</i> , 2018, 18, e1700444.	1.3	34
29	Gerstmann-Str�ussler-Scheinker Disease Amyloid Protein Polymerizes According to the "Dock-and-Lock" Model. <i>Journal of Biological Chemistry</i> , 2006, 281, 843-849.	1.6	33
30	Rare variants in LRRK1 and Parkinson's disease. <i>Neurogenetics</i> , 2014, 15, 49-57.	0.7	33
31	The LRRK2 signalling system. <i>Cell and Tissue Research</i> , 2018, 373, 39-50.	1.5	31
32	Advances in protein-protein interaction network analysis for Parkinson's disease. <i>Neurobiology of Disease</i> , 2021, 155, 105395.	2.1	31
33	Tau Mutations Serve as a Novel Risk Factor for Cancer. <i>Cancer Research</i> , 2018, 78, 3731-3739.	0.4	30
34	Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo. <i>Molecular Neurodegeneration</i> , 2021, 16, 17.	4.4	29
35	MIR-NATs repress MAPT translation and aid proteostasis in neurodegeneration. <i>Nature</i> , 2021, 594, 117-123.	13.7	29
36	Pathogenic LRRK2 Mutations Do Not Alter Gene Expression in Cell Model Systems or Human Brain Tissue. <i>PLoS ONE</i> , 2011, 6, e22489.	1.1	27

#	ARTICLE	IF	CITATIONS
37	Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology. <i>Brain Research</i> , 2018, 1701, 75-84.	1.1	25
38	LRRK2 and autophagy: a common pathway for disease. <i>Biochemical Society Transactions</i> , 2012, 40, 1147-1151.	1.6	22
39	Leucine-rich repeat kinase 2 and lysosomal dyshomeostasis in Parkinson disease. <i>Journal of Neurochemistry</i> , 2020, 152, 273-283.	2.1	21
40	PINOT: an intuitive resource for integrating protein-protein interactions. <i>Cell Communication and Signaling</i> , 2020, 18, 92.	2.7	21
41	mTOR independent alteration in ULK1 Ser758 phosphorylation following chronic LRRK2 kinase inhibition. <i>Bioscience Reports</i> , 2018, 38, .	1.1	16
42	Network Analysis for Complex Neurodegenerative Diseases. <i>Current Genetic Medicine Reports</i> , 2020, 8, 17-25.	1.9	14
43	GTP binding controls complex formation by the human ROCO protein MASL 1. <i>FEBS Journal</i> , 2014, 281, 261-274.	2.2	13
44	GTP binding and intramolecular regulation by the ROC domain of Death Associated Protein Kinase 1. <i>Scientific Reports</i> , 2012, 2, 695.	1.6	12
45	Protein network analysis reveals selectively vulnerable regions and biological processes in FTD. <i>Neurology: Genetics</i> , 2018, 4, e266.	0.9	12
46	Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia. <i>Scientific Reports</i> , 2019, 9, 10854.	1.6	9
47	LRRK2: A Problem Lurking in Vesicle Trafficking?. <i>Journal of Neuroscience</i> , 2011, 31, 9787-9788.	1.7	8
48	Integrating protein networks and machine learning for disease stratification in the Hereditary Spastic Paraplegias. <i>IScience</i> , 2021, 24, 102484.	1.9	8
49	An integrated genomic approach to dissect the genetic landscape regulating the cell-to-cell transfer of α -synuclein. <i>Cell Reports</i> , 2021, 35, 109189.	2.9	8
50	C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTL cohorts. <i>Neurology</i> , 2020, 95, e3288-e3302.	1.5	7
51	<i>SLITRK2</i> , an X-linked modifier of the age at onset in <i>C9orf72</i> frontotemporal lobar degeneration. <i>Brain</i> , 2021, 144, 2798-2811.	3.7	7
52	The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation. <i>Brain Research</i> , 2022, 1778, 147781.	1.1	7
53	Measuring Lactase Enzymatic Activity in the Teaching Lab. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	6
54	Protein interaction network analysis reveals genetic enrichment of immune system genes in frontotemporal dementia. <i>Neurobiology of Aging</i> , 2022, 116, 67-79.	1.5	2

#	ARTICLE	IF	CITATIONS
55	[O2â€“03â€“02]: PROTEIN NETWORK ANALYSIS TO PRIORITIZE CANDIDATE GENES AND PATHWAYS FOR SPORADIC DISEASE: A COMPARISON BETWEEN FRONTOTEMPORAL DEMENTIA AND PARKINSON'S DISEASE. Alzheimer's and Dementia, 2017, 13, P555.	0.4	1
56	Mendelian and Sporadic FTD: Disease Risk and Avenues from Genetics to Disease Pathways Through In Silico Modelling. Advances in Experimental Medicine and Biology, 2021, 1281, 283-296.	0.8	1
57	Genetic Risk Factors for Sporadic Frontotemporal Dementia. , 2018, , 147-186.		1
58	Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line. International Journal of Molecular Sciences, 2022, 23, 6935.	1.8	1
59	Exploration of the endoâ€“lysosomal pathway genes in frontotemporal dementia: The use of proteinâ€“protein interaction networks to prioritize rareâ€“variant association analysis results. Alzheimer's and Dementia, 2020, 16, e043624.	0.4	0